Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries

Journal of Neuroimmunology

Volumn 223, Issue 1-2, 2010, Pages 104-114

  Medecigo, M ^a   Manoutcharian, K ^a   Vasilevko, V ^d   Govezensky, T ^a   Munguia, M E ^a   Becerril, B ^c   Luz Madrigal, A ^a,b   Vaca, L ^b   Cribbs, D H ^d,e   Gevorkian, G ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO DE FISIOLOGÍA CELULAR   (Mexico)

^c INSTITUTO DE BIOTECNOLOGÍA   (Mexico)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Domain antibody; Recombinant antibody fragment

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; COAT PROTEIN COMPLEX II; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY LIBRARY; ANTIGEN EXPRESSION; ARTICLE; BIOPANNING; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IN VITRO STUDY; MOLECULAR WEIGHT; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES, MONOCLONAL; BACTERIOPHAGE M13; BINDING SITES, ANTIBODY; CELL LINE, TUMOR; EPITOPES; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 77953540108     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.03.023     Document Type: Article

References (61)

1. Acero G., Manoutcharian K., Vasilevko V., Munguia M.E., Govezensky T., Coronas G., Luz-Madrigal A., Cribbs D., Gevorkian G. Immunodominant epitope and properties of pyroglutamate-modified Aβ-specific antibodies produced in rabbits. J. Neuroimmunol. 2009, 213:39-46.
2. Bacskai B.J., Kajdasz S.T., McLellan M.E., Games D., Seubert P., Schenk D., Hyman B.T. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci. 2002, 22:7873-7878.
3. Bard F., Cannon C., Barbour R., Burke R.L., Games H., Grajeda T., Guido K., Hu J., Huang K., Johnson-Wood K., Khan D., Kholodenko M., Lee I., Lieberburg R., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch K., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid-β peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat. Med. 2000, 6:916-919.
4. Brody D.L., Holtzman D.M. Active and passive immunotherapy for neurodegenerative disorders. Annu. Rev. Neurosci. 2008, 31:175-193.
5. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8:79-84.
6. -/- knock-out mice. J. Neurosci. 2003, 23:8532-8538.
7. DeBernardis F., Liu H., O'Mahony R., La Valle R., Bartollino S., Sandini S., Grant S., Brewis N., Tomlinson I., Basset R.C., Holton J., Roitt I.M., Cassone A. Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J. Infect. Dis. 2007, 195:149-157.
8. Demarest S.J., Glaser S.M. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr. Opin. Drug Discov. Dev. 2008, 11:675-687.
9. Frenkel D., Solomon B., Benhar I. Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single-chain antibody. J. Neuroimmunol. 2000, 106:23-31.
10. Fukuchi K.-I., Tahara K., Kim H.-D., Maxwell J.A., Lewis T.L., Accavitti-Loper M.A., Kim H., Ponnazhagan S., Lalonde R. Anti-Aβ single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol. Dis. 2006, 23:502-511.
11. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., Orgogozo J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562. AN1792(QS-21)-201 Study Team.
12. Gouras G.K., Almeida C.G., Takahashi R.H. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol. Aging 2005, 26:1235-1244.
13. Gueorguieva D., Li S., Walsh N., Mukerji A., Tanha J., Pandey S. Identification of single-domain, Bax-specific intrabodies that confer resistance to mammalian cells against oxidative-stress-induced apoptosis. FASEB J. 2006, 20:2636-2638.
14. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol., Cell Biol. 2007, 8:101-112.
15. Habicht G., Haupt C., Friedrich R.P., Hortschansky P., Sachse C., Meinhardt J., Wieligmann K., Gellermann G.P., Brodhun M., Gotz J., Halbhuber K.-J., Rocken C., Horn U., Fandrich M. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils. Proc. Natl Acad. Sci. USA 2007, 104:19232-19237.
16. Harmsen M.M., De Haard H.J. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 2007, 77:13-22.
17. Hartman R.E., Izumi Y., Bales K.R., Paul S.M., Wozniak D.F., Holtzman D.M. Treatment with an amyloid-β antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J. Neurosci. 2005, 25:6213-6220.
18. Head E., Pop V., Vasilevko V., Hill M., Saing T., Sarsoza F., Nistor M., Christie L.A., Milton S., Glabe C., Barrett E., Cribbs D. A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J. Neurosci. 2008, 28:3555-3566.
19. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 2005, 23:1126-1136.
20. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jines R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A.R. Long-term effects of Aβ42 immunization in Alzheimer's disease: follow-up of a randomized, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
21. Holt L.J., Herring C., Jespers L.S., Woolven B.P., Tomlinson I.M. Domain antibodies: proteins for therapy. Trends Biotechnol. 2003, 21:484-490.
22. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
23. Janus C., Pearson J., McLaurin J., Mattews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Neslin D., French J., Mount N.T.J., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St.George-Hyslop P., Westaway D. Ab peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
24. Klein W.L. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 2002, 41:345-352.
25. Klyubin I., Walsh D.M., Lemere C.A., Cullen W.K., Shankar G.M., Betts V., Spooner E.T., Jiang L., Anwyl R., Selkoe D.J., Rowan M.J. Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 2005, 11:556-561.
26. Koenigsknecht-Talboo J., Mayer-Luehmann M., Parsadanian M., Garcia-Alloza M., Finn M.B., Hyman B.T., Bacskai B.J., Holtzmann D.M. Rapid microglial response around amyloid pathology after systemic anti-Ab antibody administration in PDAPP mice. J. Neurosci. 2008, 28:14156-14164.
27. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., Younkin S., Ashe K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 2002, 22:6331-6335.
28. La Ferla F.M., Green K.N., Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev., Neurosci. 2007, 8:499-509.
29. Lafaye P., Achour I., England P., Duyckaerts C., Rougeon F. Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. Mol. Immunol. 2008, 46:695-704.
30. Lecerf J.-M., Shirley T.L., Zhu Q., Kazantsev A., Amersdorfer P., Housman D.E., Messer A., Huston J.S. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc. Natl Acad. Sci. USA 2001, 98:4764-4769.
31. Lee E.B., Leng L.Z., Lee V.M.-Y., Trojanowski J.Q. Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. FEBS Lett. 2005, 579:2564-2568.
32. Lemere C.A., Beierschmitt A., Iglesias M., Spooner E.T., Bloom J.K., Leverone J.F., Zheng J.B., Seabrook T.J., Louard D., Li D., Selkoe D.J., Palmour R.M., Ervin F.R. Alzheimer's disease Aβ vaccine reduces central nervous system Aβ levels in a non-human primate, the Caribbean vervet. Am. J. Pathol. 2004, 165:283-297.
33. Levites Y., Das P., Price D.W., Rochette M.J., Kostura L.A., McGowan E.M., Murphy M.P., Golde T.E. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J. Clin. Invest. 2006, 116:193-201.
34. Lichtlen P., Mohajeri M.H. Antibody-based approaches in Alzheimer's research. Safety, pharmacokinetics, metabolism, and analytical tools. J. Neurochem. 2008, 104:859-874.
35. Lue L.-F., Walker D.G. Modeling Alzheimer's disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid beta peptide. J. Neurosci. Res. 2002, 70:599-610.
36. Luz-Madrigal A., Clapp C., Aranda J., Vaca L. In vivo transcriptional targeting into the retinal vasculature using recombinant baculovirus carrying the human flt-1 promoter. Virol. J. 2007, 4:88.
37. Manoutcharian K., Acero G., Munguia M.E., Montero J.A., Govezensky T., Cao C., Ugen K., Gevorkian G. Amyloid-beta peptide specific single chain Fv antibodies isolated from an immune phage display library. J. Neuroimmunol. 2003, 145:12-17.
38. Manoutcharian K., Acero G., Munguia M.E., Becerril B., Massieu L., Govezensky T., Ortiz E., Marks J.D., Cao C., Ugen K., Gevorkian G. Human single chain Fv antibodies and a complementarity determining region-derived peptide binding to amyloid beta 1-42. Neurobiol. Dis. 2004, 17:114-121.
39. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 1999, 46:860-866.
40. Meli G., Visintin M., Cannistraci I., Cattaneo A. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-β oligomers. J. Mol. Biol. 2009, 387:584-606.
41. Munch G., Robinson S.R. Potential neurotoxic inflammatory responses to Aβ vaccination in humans. J. Neural Transm. 2002, 109:1081-1087.
42. Morgan D. Immunotherapy for Alzheimer's disease. J. Alzheimer's Dis. 2006, 9:425-432.
43. O'Callaghan P., Sandwall E., Li J.-P., Ravid R., Guan Z.-Z., van Kuppevelt T.H., Nilsson L.N.G., Ingelsson M., Hyman B.T., Kalimo H., Lindahl U., Lannfelt L., Zhang X. Heparan sulfate accumulation with Ab deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells. Brain Pathol. 2008, 18:548-561.
44. Petrushina I., Ghochikyan A., Mkrtchyan M., Mamikonyan G., Movsesyan N., Davtyan H., Patel A., Head E., Cribbs D.H., Agadjanyan M.G. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J. Neurosci. 2007, 27:12721-12731.
45. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., Mathews P.M., Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002, 298:1379.
46. Racke M.M., Boone L.I., Hepburn D.L., Parsadanian M., Bryan M.T., Ness D.K., Piroozi K.S., Jordan W.H., Brown D.D., Hoffman W.P., Holtzman D.M., Bales K.R., Gitter B.D., May P.C., Paul S.M., DeMattos R.B. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 2005, 25:629-636.
47. Riaño-Umbarila L., Juarez-Gonzalez V.R., Olamendi-Portugal T., Ortiz-Leon M., Possani L.D., Becerril B. A strategy for the generation of specific human antibodies by direct evolution and phage display. An example of a single-chain antibody fragment that neutralizes a major component of scorpion venom. FEBS J. 2005, 272:2591-2601.
48. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
49. Shankar G.M., Li S., Mehta T.H., Garcia Munoz A., Shepardson N.E., Smith I., Brett F.M., Farell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
50. Spires-Jones T.L., Mielke M.L., Rozkalne A., Mayer-Luehmann M., de Calignon A., Bacskai B.J., Schenk D., Hyman B.T. Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiol. Dis. 2009, 33:213-220.
51. Tammer A.H., Coia G., Cappai R., Fuller S., Masters C.L., Hudson P., Underwood J.R. Generation of a recombinant Fab antibody reactive with the Alzheimer's disease-related Aβ peptide 2002.
52. Townsend M., Shankar G.M., Mehta T., Walsh D.M., Selkoe D.J. Effects of secreted oligomers of amyloid beta-protein in hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 2006, 572(Pt2):477-492.
53. Vasilevko V., Xu F., Previti M.L., Van Nostrand W.E., Cribbs D.H. Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice. J. Neurosci. 2007, 27:13376-13383.
54. Visintin M., Settanni G., Maritan A., Graziosi S., Marks J.D., Cattaneo A. The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J. Mol. Biol. 2002, 317:73-83.
55. Walsh D.M., Selkoe D.J. Aβ oligomers - a decade of discovery. J. Neurochem. 2007, 101:1172-1184.
56. Weisser N.E., Hall J.C. Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnol. Adv. 2009, 27:502-520.
57. Wilcock D.M., Colton C.A. Anti-amyloid beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J. Alzheimer's Dis. 2008, 15:555-569.
58. Wilcock D.M., Alamed J., Gottschall P.E., Grimm J., Rosental A., Pons J., Ronan V., Symmonds K., Gordon M.N., Morgan D. Deglycosylated anti-amyloid-β antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J. Neurosci. 2006, 26:5340-5346.
59. Wilcock D.M., Gharkholonarehe N., Van Nostrand W., Davis J., Vitek M.P., Colton C.A. Amyloid reduction by amyloid-β vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J. Neurosci. 2009, 29:7957-7965.
60. Wisniewski T., Konietzko U. Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol. 2008, 7:805-811.
61. Zameer A., Kasturirangan S., Emadi S., Nimmagadda S.V., Sierks M.R. Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. J. Mol. Biol. 2008, 384:917-928.